← Back to Search

Genetic Testing

Genetic Testing for Prostate Cancer Screening (ProGRESS Trial)

N/A
Recruiting
Led By Jason L Vassy, MD MPH
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 years
Awards & highlights

ProGRESS Trial Summary

This trial will test if a genetic test can help identify which men are at highest risk for prostate cancer and who don't need biopsies. It could improve how male Veterans are screened for prostate cancer.

Who is the study for?
The ProGRESS study is for male Veterans aged 55-69 who regularly receive care from the VA. It's designed to help those at risk of prostate cancer and aims to reduce unnecessary biopsies in men with low risk by using genetic testing.Check my eligibility
What is being tested?
This trial tests a precision screening intervention based on genetic testing against usual care methods. The goal is to see if this new approach more accurately identifies men at high or low risk for significant prostate cancer.See study design
What are the potential side effects?
Since the intervention involves genetic testing rather than medication, traditional side effects are not applicable. However, there may be some psychological impact or anxiety associated with learning about one's genetic risk.

ProGRESS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Diagnosis of clinically significant prostate cancer
Negative prostate biopsy
Secondary outcome measures
Diagnosis of prostate cancer
PSA testing
Prostate MRI
+3 more
Other outcome measures
Acceptability of the precision prostate cancer screening intervention
Adherence to precision cancer screening recommendations
Rare pathogenic/likely pathogenic variants

ProGRESS Trial Design

2Treatment groups
Experimental Treatment
Group I: Usual careExperimental Treatment1 Intervention
Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
Group II: Precision screening interventionExperimental Treatment2 Interventions
The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,611 Previous Clinical Trials
3,300,284 Total Patients Enrolled
14 Trials studying Prostate Cancer
3,785 Patients Enrolled for Prostate Cancer
Jason L Vassy, MD MPHPrincipal InvestigatorVA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2 Previous Clinical Trials
662 Total Patients Enrolled

Media Library

Precision screening intervention (Genetic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT05926102 — N/A
Prostate Cancer Research Study Groups: Precision screening intervention, Usual care
Prostate Cancer Clinical Trial 2023: Precision screening intervention Highlights & Side Effects. Trial Name: NCT05926102 — N/A
Precision screening intervention (Genetic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05926102 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the current protocol admit participants who are aged 50 or older?

"Those who fit the eligibility criteria for this research project must be between 55 and 69 years old."

Answered by AI

Are there any openings to be part of this clinical trial?

"According to clinicaltrials.gov, the posting of this medical trial has been since updated and is no longer searching for participants. It was first posted on October 1st 2023 and last modified June 21st 2023; however, 1321 other trials are still actively recruiting patients at present."

Answered by AI

What outcomes are investigators expecting to observe through this trial?

"This long-term clinical trial, lasting about 7 years, will measure the efficacy of Prostate biopsy as its primary endpoint. Secondary objectives include Negative prostate biopsy, PSA testing and Prostate MRI which can be determined from VA or survey data."

Answered by AI

What qualifications are needed to participate in this clinical trial?

"This medical trial has 5000 slots, and applicants must be between the ages of 55-69, with a diagnosis of prostate cancer."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
2024. "The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05926102.
~3333 spots leftby Sep 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top